Book a Meeting

Non-Fucosylated Anti-Human CD24 (SWA11) Therapeutic Antibody (CAT#: BioBet-650ZP) Datasheet

Target
CD24
Isotype
IgG2a
Description
ADCC-Enhanced anti-CD24 (SWA11) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD24 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD24
Full Name
CD24 molecule
Background
This gene encodes a sialoglycoprotein that is expressed on mature granulocytes and B cells and modulates growth and differentiation signals to these cells. The precursor protein is cleaved to a short 32 amino acid mature peptide which is anchored via a glycosyl phosphatidylinositol (GPI) link to the cell surface. This gene was missing from previous genome assemblies, but is properly located on chromosome 6. Non-transcribed pseudogenes have been designated on chromosomes 1, 15, 20, and Y. Alternative splicing results in multiple transcript variants.
Alternative Names
CD24; CD24 molecule; CD24A; signal transducer CD24; CD24 antigen (small cell lung carcinoma cluster 4 antigen)
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CD24 include Bile Duct Cancer and Multiple Sclerosis.
Related Pathways
Its related pathways are Hematopoietic cell lineage and L1CAM interactions.
Function
May play a key role in the differentiation of different cell types. The signal pathway can be triggered by the binding of lectin-like ligands to CD24 carbohydrates, and is conducted by the release of GPI-anchor-derived second messengers. Regulate b cell activation response. Promote the silver-dependent proliferation of b cells and prevent their terminal differentiation into antibody-forming cells. The SIGLEC10-related may be involved in the selective suppression of immune response to DAMPs such as HMGB1, HSP70 and HSP90. Play a role in controlling autoimmunity (through similarity).
Post-translational modifications
Extensively O-glycosylated.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2a
Antibody Clone
SWA11
Host
Humanized
Species Reactivity
Human
Description
Anti-CD24 antibody and adjuvant combinations thereof with chemotherapeutic agents or toxins, which can be used to inhibit growth of CD24-expressing cancer cells and prevent and treat cancer are provided.
Indication
Cancer

Cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany